In a study conducted in 2022, it was demonstrated that lower levels of biomarkers such as fibrinogen, fractalkine, brain natriuretic peptide (BNP), high-sensitivity troponin-T (hsTnT), BTP, and KIM-1 are associated with a slower deterioration of kidney function among patients with non-albuminuric CKD in DN compared to those patients with normal kidney function [138]. This evidence concerns the gene HAVCR1 and liver dysplastic nodule.